Antibody Drug Conjugates (ADCS) Market

Antibody Drug Conjugates (ADCS) Market - Global Industry Assessment & Forecast

Healthcare

# Pages:

155

Base Year:

2022

Feb - 2022

Format:

Report Code:

VMR-1280

Segments Covered

By Application Breast Cancer, Urothelial Cancer & Bladder Cancer, Other Cancer, Blood Cancer
By Technology Cleavable Linker, Non-Cleavable Linker, Linkerless
By Region North America, Europe, Asia Pacific, Latin America, Middle East & Africa

Standard License

$ 4299 USD

Multi User License

$ 6599 USD

Enterprise License

$ 6999 USD

Snapshot

Base Year:	2022
Forecast Years:	2023 - 2030
Historical Years:	2017 - 2021
Revenue 2022:	USD 4.75 Billion
Revenue 2030:	USD 18.84 Billion
Revenue CAGR (2023 - 2030):	18.80%
Fastest Growing Region (2023 - 2030)	Asia Pacific
Largest Region (2022):	North America

Customization Offered

Cross-segment Market Size and Analysis for Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market Dynamics
Region Level Market Share
Import Export Analysis
Production Analysis
Others Request Customization Speak To Analyst

Executive Dashboard
1. Strategic Imperatives
Premium Insights
1. Top 3 Trends to Watch
2. Demand and Supply Trends
3. Top 3 Strategies Followed by Major Players
4. Top 3 Predictions by Vantage Market Research
5. Top Investment Pockets
6. Insights from Primary Respondents
Global Antibody Drug Conjugates (ADCS) Market - Segment Analysis
1. Overview
2. Global Antibody Drug Conjugates (ADCS) Market, 2016 - 2028 (USD Million)
3. Global Antibody Drug Conjugates (ADCS) Market - by Application
  1. By Breast Cancer
  2. By Urothelial Cancer & Bladder Cancer
  3. By Other Cancer
  4. By Blood Cancer
4. Global Antibody Drug Conjugates (ADCS) Market - by Technology
  1. By Cleavable Linker
  2. By Non-Cleavable Linker
  3. By Linkerless
5. Global Antibody Drug Conjugates (ADCS) Market - by region
  1. North America
  2. Europe
  3. Asia Pacific
  4. Latin America
  5. Middle East & Africa
6. Market comparative analysis
North America Antibody Drug Conjugates (ADCS) Market - Segment Analysis
1. Overview
2. North America Antibody Drug Conjugates (ADCS) Market, 2016 - 2028 (USD Million)
3. North America Antibody Drug Conjugates (ADCS) Market, by Application
  1. By Breast Cancer
  2. By Urothelial Cancer & Bladder Cancer
  3. By Other Cancer
  4. By Blood Cancer
4. North America Antibody Drug Conjugates (ADCS) Market, by Technology
  1. By Cleavable Linker
  2. By Non-Cleavable Linker
  3. By Linkerless
5. North America Antibody Drug Conjugates (ADCS) Market, by Country
  1. U.S.
    1. U.S. Antibody Drug Conjugates (ADCS) Market, By Application
      1. By Breast Cancer
      2. By Urothelial Cancer & Bladder Cancer
      3. By Other Cancer
      4. By Blood Cancer
    2. U.S. Antibody Drug Conjugates (ADCS) Market, By Technology
      1. By Cleavable Linker
      2. By Non-Cleavable Linker
      3. By Linkerless
  2. Canada
    1. Canada Antibody Drug Conjugates (ADCS) Market, By Application
      1. By Breast Cancer
      2. By Urothelial Cancer & Bladder Cancer
      3. By Other Cancer
      4. By Blood Cancer
    2. Canada Antibody Drug Conjugates (ADCS) Market, By Technology
      1. By Cleavable Linker
      2. By Non-Cleavable Linker
      3. By Linkerless
  3. Mexico
    1. Mexico Antibody Drug Conjugates (ADCS) Market, By Application
      1. By Breast Cancer
      2. By Urothelial Cancer & Bladder Cancer
      3. By Other Cancer
      4. By Blood Cancer
    2. Mexico Antibody Drug Conjugates (ADCS) Market, By Technology
      1. By Cleavable Linker
      2. By Non-Cleavable Linker
      3. By Linkerless
Europe Antibody Drug Conjugates (ADCS) Market - Segment Analysis
1. Overview
2. Europe Antibody Drug Conjugates (ADCS) Market, 2016 - 2028 (USD Million)
3. Europe Antibody Drug Conjugates (ADCS) Market, by Application
  1. By Breast Cancer
  2. By Urothelial Cancer & Bladder Cancer
  3. By Other Cancer
  4. By Blood Cancer
4. Europe Antibody Drug Conjugates (ADCS) Market, by Technology
  1. By Cleavable Linker
  2. By Non-Cleavable Linker
  3. By Linkerless
5. Europe Antibody Drug Conjugates (ADCS) Market, by Country
  1. Germany
    1. Germany Antibody Drug Conjugates (ADCS) Market, By Application
      1. By Breast Cancer
      2. By Urothelial Cancer & Bladder Cancer
      3. By Other Cancer
      4. By Blood Cancer
    2. Germany Antibody Drug Conjugates (ADCS) Market, By Technology
      1. By Cleavable Linker
      2. By Non-Cleavable Linker
      3. By Linkerless
  2. UK
    1. UK Market, By Application
      1. By Breast Cancer
      2. By Urothelial Cancer & Bladder Cancer
      3. By Other Cancer
      4. By Blood Cancer
    2. UK Market, By Technology
      1. By Cleavable Linker
      2. By Non-Cleavable Linker
      3. By Linkerless
  3. France
    1. France Antibody Drug Conjugates (ADCS) Market, By Application
      1. By Breast Cancer
      2. By Urothelial Cancer & Bladder Cancer
      3. By Other Cancer
      4. By Blood Cancer
    2. France Antibody Drug Conjugates (ADCS) Market, By Technology
      1. By Cleavable Linker
      2. By Non-Cleavable Linker
      3. By Linkerless
  4. Spain
    1. Spain Antibody Drug Conjugates (ADCS) Market, By Application
      1. By Breast Cancer
      2. By Urothelial Cancer & Bladder Cancer
      3. By Other Cancer
      4. By Blood Cancer
    2. Spain Antibody Drug Conjugates (ADCS) Market, By Technology
      1. By Cleavable Linker
      2. By Non-Cleavable Linker
      3. By Linkerless
  5. Italy
    1. Italy Antibody Drug Conjugates (ADCS) Market, By Application
      1. By Breast Cancer
      2. By Urothelial Cancer & Bladder Cancer
      3. By Other Cancer
      4. By Blood Cancer
    2. Italy Antibody Drug Conjugates (ADCS) Market, By Technology
      1. By Cleavable Linker
      2. By Non-Cleavable Linker
      3. By Linkerless
  6. BENELUX
    1. BENELUX Antibody Drug Conjugates (ADCS) Market, By Application
      1. By Breast Cancer
      2. By Urothelial Cancer & Bladder Cancer
      3. By Other Cancer
      4. By Blood Cancer
    2. BENELUX Antibody Drug Conjugates (ADCS) Market, By Technology
      1. By Cleavable Linker
      2. By Non-Cleavable Linker
      3. By Linkerless
  7. Rest of Europe
    1. Rest Of Europe Antibody Drug Conjugates (ADCS) Market, By Application
      1. By Breast Cancer
      2. By Urothelial Cancer & Bladder Cancer
      3. By Other Cancer
      4. By Blood Cancer
    2. Rest Of Europe Antibody Drug Conjugates (ADCS) Market, By Technology
      1. By Cleavable Linker
      2. By Non-Cleavable Linker
      3. By Linkerless
Asia Pacific Antibody Drug Conjugates (ADCS) Market - Segment Analysis
1. Overview
2. Asia Pacific Antibody Drug Conjugates (ADCS) Market, 2016 - 2028 (USD Million)
3. Asia Pacific Antibody Drug Conjugates (ADCS) Market, by Application
  1. By Breast Cancer
  2. By Urothelial Cancer & Bladder Cancer
  3. By Other Cancer
  4. By Blood Cancer
4. Asia Pacific Antibody Drug Conjugates (ADCS) Market, by Technology
  1. By Cleavable Linker
  2. By Non-Cleavable Linker
  3. By Linkerless
5. Asia Pacific Antibody Drug Conjugates (ADCS) Market, by Country
  1. China
    1. China Antibody Drug Conjugates (ADCS) Market, By Application
      1. By Breast Cancer
      2. By Urothelial Cancer & Bladder Cancer
      3. By Other Cancer
      4. By Blood Cancer
    2. China Antibody Drug Conjugates (ADCS) Market, By Technology
      1. By Cleavable Linker
      2. By Non-Cleavable Linker
      3. By Linkerless
  2. Japan
    1. Japan Antibody Drug Conjugates (ADCS) Market, By Application
      1. By Breast Cancer
      2. By Urothelial Cancer & Bladder Cancer
      3. By Other Cancer
      4. By Blood Cancer
    2. Japan Antibody Drug Conjugates (ADCS) Market, By Technology
      1. By Cleavable Linker
      2. By Non-Cleavable Linker
      3. By Linkerless
  3. India
    1. India Antibody Drug Conjugates (ADCS) Market, By Application
      1. By Breast Cancer
      2. By Urothelial Cancer & Bladder Cancer
      3. By Other Cancer
      4. By Blood Cancer
    2. India Antibody Drug Conjugates (ADCS) Market, By Technology
      1. By Cleavable Linker
      2. By Non-Cleavable Linker
      3. By Linkerless
  4. South Korea
    1. South Korea Antibody Drug Conjugates (ADCS) Market, By Application
      1. By Breast Cancer
      2. By Urothelial Cancer & Bladder Cancer
      3. By Other Cancer
      4. By Blood Cancer
    2. South Korea Antibody Drug Conjugates (ADCS) Market, By Technology
      1. By Cleavable Linker
      2. By Non-Cleavable Linker
      3. By Linkerless
  5. South East Asia
    1. South East Asia Antibody Drug Conjugates (ADCS) Market, By Application
      1. By Breast Cancer
      2. By Urothelial Cancer & Bladder Cancer
      3. By Other Cancer
      4. By Blood Cancer
    2. South East Asia Antibody Drug Conjugates (ADCS) Market, By Technology
      1. By Cleavable Linker
      2. By Non-Cleavable Linker
      3. By Linkerless
  6. Rest of Asia Pacific
    1. Rest of Asia Pacific Antibody Drug Conjugates (ADCS) Market, By Application
      1. By Breast Cancer
      2. By Urothelial Cancer & Bladder Cancer
      3. By Other Cancer
      4. By Blood Cancer
    2. Rest of Asia Pacific Antibody Drug Conjugates (ADCS) Market, By Technology
      1. By Cleavable Linker
      2. By Non-Cleavable Linker
      3. By Linkerless
Latin America Antibody Drug Conjugates (ADCS) Market - Segment Analysis
1. Overview
2. Latin America Antibody Drug Conjugates (ADCS) Market, 2016 - 2028 (USD Million)
3. Latin America Antibody Drug Conjugates (ADCS) Market, by Application
  1. By Breast Cancer
  2. By Urothelial Cancer & Bladder Cancer
  3. By Other Cancer
  4. By Blood Cancer
4. Latin America Antibody Drug Conjugates (ADCS) Market, by Technology
  1. By Cleavable Linker
  2. By Non-Cleavable Linker
  3. By Linkerless
5. Latin America Antibody Drug Conjugates (ADCS) Market, by Country
  1. Brazil
    1. Brazil Antibody Drug Conjugates (ADCS) Market, By Application
      1. By Breast Cancer
      2. By Urothelial Cancer & Bladder Cancer
      3. By Other Cancer
      4. By Blood Cancer
    2. Brazil Antibody Drug Conjugates (ADCS) Market, By Technology
      1. By Cleavable Linker
      2. By Non-Cleavable Linker
      3. By Linkerless
  2. Argentina
    1. Argentina Antibody Drug Conjugates (ADCS) Market, By Application
      1. By Breast Cancer
      2. By Urothelial Cancer & Bladder Cancer
      3. By Other Cancer
      4. By Blood Cancer
    2. Argentina Antibody Drug Conjugates (ADCS) Market, By Technology
      1. By Cleavable Linker
      2. By Non-Cleavable Linker
      3. By Linkerless
  3. Rest of Latin America
    1. Rest of Latin America Antibody Drug Conjugates (ADCS) Market, By Application
      1. By Breast Cancer
      2. By Urothelial Cancer & Bladder Cancer
      3. By Other Cancer
      4. By Blood Cancer
    2. Rest of Latin America Antibody Drug Conjugates (ADCS) Market, By Technology
      1. By Cleavable Linker
      2. By Non-Cleavable Linker
      3. By Linkerless
Middle East & Africa Antibody Drug Conjugates (ADCS) Market - Segment Analysis
1. Overview
2. Middle East & Africa Antibody Drug Conjugates (ADCS) Market, 2016 - 2028 (USD Million)
3. Middle East & Africa Antibody Drug Conjugates (ADCS) Market, by Application
  1. By Breast Cancer
  2. By Urothelial Cancer & Bladder Cancer
  3. By Other Cancer
  4. By Blood Cancer
4. Middle East & Africa Antibody Drug Conjugates (ADCS) Market, by Technology
  1. By Cleavable Linker
  2. By Non-Cleavable Linker
  3. By Linkerless
5. Middle East & Africa Antibody Drug Conjugates (ADCS) Market, by Country
  1. GCC Countries
    1. GCC Countries Antibody Drug Conjugates (ADCS) Market, By Application
      1. By Breast Cancer
      2. By Urothelial Cancer & Bladder Cancer
      3. By Other Cancer
      4. By Blood Cancer
    2. GCC Countries Antibody Drug Conjugates (ADCS) Market, By Technology
      1. By Cleavable Linker
      2. By Non-Cleavable Linker
      3. By Linkerless
  2. South Africa
    1. South Africa Antibody Drug Conjugates (ADCS) Market, By Application
      1. By Breast Cancer
      2. By Urothelial Cancer & Bladder Cancer
      3. By Other Cancer
      4. By Blood Cancer
    2. South Africa Antibody Drug Conjugates (ADCS) Market, By Technology
      1. By Cleavable Linker
      2. By Non-Cleavable Linker
      3. By Linkerless
  3. Rest of Middle East & Africa
    1. Rest of Middle East & Africa Antibody Drug Conjugates (ADCS) Market, By Application
      1. By Breast Cancer
      2. By Urothelial Cancer & Bladder Cancer
      3. By Other Cancer
      4. By Blood Cancer
    2. Rest of Middle East & Africa Antibody Drug Conjugates (ADCS) Market, By Technology
      1. By Cleavable Linker
      2. By Non-Cleavable Linker
      3. By Linkerless
Key Market Dynamics
1. Introduction
2. Market Drivers
3. Market Restraints
4. Market Opportunities
5. Porter's Five Forces Analysis
6. PEST Analysis
7. Regulatory Landscape
8. Technology Landscape
9. Regional Market Trends
COVID 19 Impact Analysis
1. Key strategies undertaken by companies to tackle COVID-19
2. Short term dynamics
3. Long term dynamics
Marketing Stratagy Analysis
1. Marketing Channel
2. Direct Marketing
3. Indirect Marketing
4. Marketing Channel Development Trends
Competative Landscape
1. Competition Matrix - 2021
2. Company Market Share Analysis - 2021
3. Key Company Activities, 2018 - 2021
4. Strategic Developments - Heat Map Analysis
5. Company Offering Evaluation
6. Company Regional Presence Evaluation
Company Profiles
1. Takeda Pharmaceutical Company Ltd. (Japan)
2. F. Hoffmann-La Roche Ltd. (US)
3. Pfizer Inc. (US)
4. AstraZeneca (Sweden)
5. Gilead Sciences Inc. (US)
6. Astellas Pharma (Japan)
7. Seagen Inc. (US)
8. Daiichi Sankyo Company Ltd. (Japan)
9. GlaxoSmithKline PLC (UK)
10. ADC Therapeutics (Switzerland)
Key Primary Respondents - VERBATIM
Discussion Guide
Customization Offered
Annexure
List of Figures
List of Tables
List of Abbreviations

Vantage Market Research | 09-Feb-2022

Antibody Drug Conjugates (ADCS) Market to Reach Valuation of USD 13.17 Billion by 2028 - Increasing Number of Clinical Trials for New Cancer Therapeutics Drive the Market

FAQ

Frequently Asked Question

What is the global demand for Antibody Drug Conjugates (ADCS) in terms of revenue?

The global Antibody Drug Conjugates (ADCS) valued at USD 4.75 Billion in 2022 and is expected to reach USD 18.84 Billion in 2030 growing at a CAGR of 18.80%.

Which are the prominent players in the market?

The prominent players in the market are Takeda Pharmaceutical Company Ltd. (Japan), F. Hoffmann-La Roche Ltd. (US), Pfizer Inc. (US), AstraZeneca (Sweden), Gilead Sciences Inc. (US), Astellas Pharma (Japan), Seagen Inc. (US), Daiichi Sankyo Company Ltd. (Japan), GlaxoSmithKline PLC (UK), ADC Therapeutics (Switzerland).

At what CAGR is the market projected to grow within the forecast period?

The market is project to grow at a CAGR of 18.80% between 2023 and 2030.

What are the driving factors fueling the growth of the market.

The driving factors of the Antibody Drug Conjugates (ADCS) include
- Significant Investment in Research and Development

Which region accounted for the largest share in the market?

North America was the leading regional segment of the Antibody Drug Conjugates (ADCS) in 2022.

Antibody Drug Conjugates (ADCS) Market

Antibody Drug Conjugates (ADCS) Market - Global Industry Assessment & Forecast

Healthcare

Segments Covered

Snapshot

Customization Offered

FAQ

Frequently Asked Question

What is the global demand for Antibody Drug Conjugates (ADCS) in terms of revenue?

Which are the prominent players in the market?

At what CAGR is the market projected to grow within the forecast period?

What are the driving factors fueling the growth of the market.

Which region accounted for the largest share in the market?

Vantage Market Research

Products & Services

Media

Contact Us

Antibody Drug Conjugates (ADCS) Market

Antibody Drug Conjugates (ADCS) Market - Global Industry Assessment & Forecast

Healthcare

Segments Covered

Snapshot

Customization Offered

FAQ

Frequently Asked Question

What is the global demand for Antibody Drug Conjugates (ADCS) in terms of revenue?

Which are the prominent players in the market?

At what CAGR is the market projected to grow within the forecast period?

What are the driving factors fueling the growth of the market.

Which region accounted for the largest share in the market?

Related Reports

Request Sample Report for Antibody Drug Conjugates (ADCS) Market

Vantage Point Interactive Dashboard